CLINICAL TRIALS PROFILE FOR PARCOPA
✉ Email this page to a colleague
All Clinical Trials for Parcopa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00139867 ↗ | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease | Completed | UCB Pharma | Phase 3 | 2004-01-01 | The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease. |
| NCT00139880 ↗ | A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease | Completed | UCB Pharma | Phase 3 | 2005-06-01 | To test whether Parcopa, a new Orally Disintegrating Tablet of Carbidopa-Levodopa, has a faster onset of action, changes in the UPDRS Motor Exam score at intervals after a single dose of Parcopa or Sinemet are being compared in 10 subjects with Parkinson's disease. Subjects 40 years or older having idiopathic PD with Hoehn and Yahr state II or III are eligible if taking a stable dose of < 200 mg carbidopa and < 2000 mg levodopa daily. At both treatment visits, either Parcopa or Sinemet, plus a placebo of the opposite tablet (ODT or conventional) are administered. The dose is the same as the subject's prestudy regimen. The primary efficacy variable, time to onset of action, is the first postdose time when a 30% decrease (30% improvement) in the total score is achieved. All UPDRS evaluations are done by a rater blinded to the active treatment received by the subject. |
| NCT00590122 ↗ | Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study | Completed | UCB Pharma | Phase 4 | 2006-10-01 | To find out if a single dose of Parcopa®, a form of levodopa that dissolves in your mouth, works faster than regular oral levodopa which is swallowed, in fluctuating PD patients. |
| NCT00590122 ↗ | Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study | Completed | Baylor College of Medicine | Phase 4 | 2006-10-01 | To find out if a single dose of Parcopa®, a form of levodopa that dissolves in your mouth, works faster than regular oral levodopa which is swallowed, in fluctuating PD patients. |
| NCT01663935 ↗ | Vision Response to Dopamine Replacement | Terminated | University of Wisconsin, Madison | Phase 2 | 2012-10-17 | The purpose of the study is to evaluate and document physiologic and functional changes in visual performance and retinal function of patients diagnosed with albinism (a dopamine deficiency state) following a trial of oral Levodopa/carbidopa treatment. |
| NCT02080819 ↗ | Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse | Completed | National Institute on Drug Abuse (NIDA) | Phase 2 | 2014-02-01 | This project proposes to investigate the role of brain connectivity in the mechanism of treatment response to dopaminergic medications in cocaine dependence. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Parcopa
Condition Name
Clinical Trial Locations for Parcopa
Trials by Country
Clinical Trial Progress for Parcopa
Clinical Trial Phase
Clinical Trial Sponsors for Parcopa
Sponsor Name
